Loproc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loproc

Quick Facts

Property Description
Active ingredient Omeprazole
Form Oral, Delayed-release capsule or Tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Gastric acid secretion inhibitor
Origin Synthetic, Substituted Benzimidazole

What Type of Drug is Loproc? (Identity and Classification)

Loproc is a synthetic, prescription-only Gastrointestinal agent whose core active ingredient is Omeprazole. It is classified globally as a Proton Pump Inhibitor (PPI), distinguishing it as a highly specific controller of stomach acid production. Omeprazole is recognized as a cornerstone PPI agent, noted for its efficacy in acid control.

This classification places Loproc chemically within the Substituted Benzimidazole class, reflecting its unique molecular structure and targeted function. As a PPI, the medication is designed for profound, consistent suppression of gastric acid secretion, which is the fundamental mechanism that defines its utility. Loproc is utilized as a Monotherapy product, containing only this single active compound to achieve its intended effect.


Loproc’s Composition and Pharmaceutical Form

Loproc is an Oral medication most commonly available in the distinctive form of a Delayed-release capsule or containing enteric-coated pellets. This specialized formulation is essential for delivering the active ingredient, Omeprazole, effectively into the body.

The specialized enteric coating protects the medication from being prematurely degraded by the acid in the stomach; the drug is meant to remain intact until it reaches the small intestine where it can be properly absorbed. This requirement for protection is a key differentiating factor of Omeprazole compared to older acid-reducing agents. This strategic delivery ensures that the Omeprazole can enter the bloodstream and travel to the stomach's parietal cells, where it is activated to perform its action.


How Does Loproc Generally Affect the Stomach? (Purpose and Core Action)

Loproc functions by directly and irreversibly blocking the Proton Pump (H^+K^+-ATPase), which is the final mechanism used by the stomach's parietal cells to produce and secrete acid. The drug effectively disables this pump, resulting in a sustained and significant reduction of both continuous (basal) and food-stimulated acid levels.

The core general purpose of this action is to serve as a potent Gastric acid secretion inhibitor, profoundly limiting the corrosive potential of stomach acid on the digestive lining. Omeprazole is a cornerstone in the management of acid-related conditions due to its unique mechanism of blocking acid production. This reliable mechanism means the medicine consistently helps reduce discomfort related to excess acid. By achieving such strong acid suppression, Loproc generally functions as an Antiulcer agent, creating an environment conducive to the protection and healing of the upper gastrointestinal tract.

What side effects are possible with Loproc?

Possible side effects and safety information

The safety profile for Loproc (Omeprazole) is structured according to official regulatory documentation, classifying adverse reactions by frequency and the body system affected. These classifications ensure a neutral description of possible side effects from government sources.


Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common (may affect up to 1 in 10 people), and include gastrointestinal issues such as abdominal pain, diarrhea, constipation, nausea, vomiting, flatulence, and headache. Effects classified as Uncommon include insomnia, dizziness, and increased liver enzymes. Rare effects include hypersensitivity reactions, hyponatremia, and acute interstitial nephritis. Certain severe reactions are classified as Very Rare, such as hepatic failure and severe cutaneous adverse reactions like Stevens-Johnson Syndrome (SJS).


Serious Safety Considerations

Official labeling documents specific, clinically important adverse events. These include the risk of Acute Tubulointerstitial Nephritis (TIN) and Severe Cutaneous Adverse Reactions (SCARs). The product is also associated with an increased risk of gastrointestinal infections, including Clostridium difficile-associated diarrhea (CDAD). Known hypersensitivity to substituted benzimidazoles is a documented constraint.


Exposure- and Duration-Related Patterns

Certain safety patterns are officially linked to treatment duration. Long-term use (one year or longer) is associated with an increased risk of osteoporosis-related bone fractures. Similarly, prolonged daily use may be associated with Vitamin B12 deficiency and the development of benign fundic gland polyps. Safety considerations exist for patients with pre-existing hepatic impairment, where a risk of hepatic failure is noted.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Loproc (Omeprazole) overdose is based on documented high-dose exposures, some involving doses up to 900 mg. The clinical manifestations observed in these cases were generally transient.

Documented Manifestations and Outcomes

The officially recognized signs of overdosage may include confusion, drowsiness, headache, blurred vision, tachycardia (increased heart rate), nausea, diaphoresis (increased sweating), flushing, and dry mouth. Regulatory documents note that in reported cases, no serious clinical outcome has been confirmed.

Immediate Action Mandated by Regulators

Official guidance requires individuals to seek emergency medical attention or contact a Poison Control Center right away for any suspected overdose. Immediate activation of emergency services is required if the affected person exhibits severe outcomes, such as trouble breathing or the inability to be awakened (unconsciousness).

Official Management Protocol

The official labeling confirms that no specific antidote is known for Omeprazole overdose. Therefore, treatment is explicitly symptomatic and supportive, directed toward managing the manifestations presented. The drug’s extensive protein binding also means it is not readily dialyzable.

Therapeutic Uses of Loproc

What Loproc Treats: Main Uses and Benefits

Loproc is relevant in situations involving certain distressing symptoms and contributes to easing the overall symptom load caused by corrosive stomach acid. It is applied in addressing conditions where acid levels may be excessive or improperly contained. The medication is commonly used to help with multiple conditions, including the healing of gastric and duodenal ulcers, the management of Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis, and the control of pathological hypersecretory states.


Symptom Relief and Tissue Protection

This therapeutic domain helps address symptoms related to physical discomfort like frequent, painful heartburn, acid regurgitation, and gnawing upper abdominal pain. Loproc may assist with the healing of sores and damaged tissue in the upper GI tract, providing supportive relief when symptoms interfere with routine activities. It is commonly used to help with the suppression of acid production, which supports general well-being during symptomatic phases. The medication may assist with reducing the risk of duodenal ulcer recurrence by eradicating H. pylori (in combination with antibiotics) and is also applied during phases of increased distress associated with rare conditions.


Quick Fact: Relief for Acid-Related Symptoms
Main Symptom Axis Burning and Sour Sensations (Heartburn, Regurgitation)
Primary Therapeutic Goal Tissue Healing and Sustained Symptom Moderation
Relevant Scenario Chronic, Frequent Symptoms and Active Ulceration

Regulatory References

  1. NIH MedlinePlus overview on Omeprazole

Eligibility and Restrictions for Use

Who can and cannot use Loproc?

The official eligibility for Loproc (Omeprazole) is strictly governed by regulatory labeling, which defines both absolute prohibitions and conditional usage based on patient status.


Absolute Contraindications

Loproc must not be used by patients with a known hypersensitivity to omeprazole, any component of its formulation, or to other medications in the substituted benzimidazole class. Use is also absolutely contraindicated in patients concurrently receiving rilpivirine-containing products or the drug nelfinavir (depending on the region’s label).


Age and Life Stage Restrictions

Use is established in adults for all labeled indications. In pediatric patients, eligibility begins at 1 month of age for certain uses, but safety and effectiveness have not been established for children younger than 1 month. For both pregnancy and lactation, use is conditional; official guidance requires that a decision be made to discontinue nursing or the drug.


Conditional Use and Screening

Use is restricted in patients with impaired hepatic function (liver disease) due to slower drug metabolism, requiring the use of caution. A regulatory rule also mandates that if a patient has a suspected gastric ulcer, gastric malignancy must be excluded before commencing treatment. Use in older adults or patients with renal impairment generally does not necessitate a specific dose adjustment.

What should I know about interactions with other medicines?

Loproc (omeprazole) interacts with numerous medicines through two primary, officially documented mechanisms: alteration of gastric acidity and inhibition of CYP enzymes. All regulatory restrictions are defined by the resulting effects on co-administered drug concentrations.


Documented Interaction Patterns

Formal Contraindicated Combination

The combination of Loproc with products containing the antiretroviral rilpivirine is formally contraindicated. This combination significantly reduces the plasma concentration of rilpivirine, risking loss of antiviral effectiveness.

Interactions Altering Drug Exposure

Loproc inhibits the CYP enzyme system (primarily CYP2C19), leading to reduced clearance and increased systemic exposure of co-administered medicines that are metabolized by this pathway. Drugs affected include diazepam, phenytoin, cilostazol, and warfarin; for the latter, monitoring of the International Normalized Ratio (INR) is required.

Interactions due to Reduced Gastric Acidity

As a potent acid inhibitor, Loproc alters the absorption of drugs that require an acidic stomach environment. This effect causes reduced plasma concentrations for antifungals like ketoconazole and certain antiretrovirals like atazanavir and nelfinavir. Conversely, the exposure of digoxin can be increased due to the reduced acidity.

Herbal Product Interaction

The herbal supplement St. John's Wort is documented to reduce Loproc's systemic exposure due to its inducing effect on metabolic enzymes.

Mechanism of Action

How Loproc Works

Loproc (ciclopirox) is an antifungal and antibacterial agent that exerts its effect through multiple, distinct pharmacodynamic domains targeting microbial physiology and host response.

Disruption of Fungal Cellular Metabolism

The primary antifungal mechanism involves the drug's activity as a chelator of polyvalent metal cations (Fe^3+ and Al^3+) essential for microbial survival. This interaction modifies the function of key metal-dependent enzymes necessary for cellular respiration and for neutralizing reactive oxygen species. The pathway modulation results in the loss of adenosine triphosphate (ATP) production and a failure in defense against oxidative stress at the cellular level.


Inhibition of Core Replication Processes

A separate mechanistic cluster focuses on the regulation of microbial growth pathways. Loproc modifies early molecular steps by disrupting DNA repair and cell cycle division signals, alongside components involved in intracellular transport. This cascade contributes to the limitation of fungal and bacterial proliferation by modulating the organism's reproductive and maintenance cycles.


Modulation of Local Inflammatory Signaling

Beyond its direct antimicrobial actions, Loproc engages host mechanisms by inhibiting the synthesis of pro-inflammatory mediators, specifically prostaglandins and leukotrienes. This pathway effect reduces mediator activity and modulates inflammatory signaling within the local tissue environment.

Dosage and Administration Information

How Loproc is Used

Loproc (omeprazole) administration is determined by the specific use scenario, dosage form, and patient population.

Administration and Handling

Loproc is primarily for oral administration as a delayed-release capsule or tablet, which must be swallowed whole. To maintain the integrity of the enteric coating, the dosage form must not be chewed or crushed. The medicine should generally be taken before eating, typically in the morning.

  • Alternative Intake: For patients unable to swallow the capsule, the pellets inside may be opened and mixed with a spoonful of applesauce or a slightly acidic liquid and swallowed immediately. The pellets must not be chewed.
  • Intravenous (IV) Use: An intravenous infusion formulation is available for use when the oral route is temporarily inappropriate.

Standard Dosing and Duration

Adult dosing is typically once daily with the following regimen examples:

Scenario Standard Adult Dose Duration Pattern
Active Duodenal Ulcer 20 mg once daily 4 weeks (up to an additional 4 weeks)
Active Gastric Ulcer 40 mg once daily 4 to 8 weeks
Maintenance of Erosive Esophagitis 20 mg once daily Long-term use (controlled studies up to 12 months)
Hypersecretory Conditions Starting dose: 60 mg once daily Adjusted to needs; daily doses > 80 mg must be given in divided administrations

Adjustments for Specific Populations

  • Pediatric Dosing: For children 1 to 16 years, the dose for conditions like GERD and erosive esophagitis is weight-based, ranging from 5 mg to 20 mg once daily.
  • Hepatic Impairment: Dose adjustments are recommended, with a daily dose of 10 mg to 20 mg often being sufficient.
  • Missed Dose: If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Loproc: Recent Clinical Evidence

This section provides a factual overview of the clinical research conducted for Loproc (Omeprazole), based on reports from regulatory bodies and peer-reviewed scientific literature. This summary describes what has been studied and what remains uncertain, without providing any medical or usage advice.


Evidence for Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis

The evidence landscape includes numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to assess patient-reported change in the frequency of heartburn and acid regurgitation. For Erosive Esophagitis, research monitored objective outcomes, specifically using endoscopy to measure the rate of change in mucosal tissue status over intervals typically lasting 4 to 8 weeks. Findings contribute to the broader evidence landscape related to the study of acid control and symptom recurrence.


Evidence for Healing Gastric and Duodenal Ulcers

Loproc was evaluated in studies addressing the status of ulcers found in the stomach (gastric) and the upper small intestine (duodenal). Research examined the time required to reach a specific, defined ulcer status, confirmed by endoscopic verification over follow-up durations of approximately four to eight weeks. Comparative evidence was observed in some studies against older acid-reducing medications. Specific research also monitored the use of Loproc in combination with antibiotics, exploring patterns of duodenal ulcer recurrence linked to H. pylori bacteria.


Research on Pathological Hypersecretory Conditions

Loproc was studied for use in rare disorders such as Zollinger–Ellison Syndrome, which involve periods of heightened symptoms and localized tissue damage. Due to the rarity of these conditions, evidence is primarily derived from long-term clinical reports and case series. These studies monitored measurements of gastric acid output over periods spanning several years.


Research Gaps and Special Populations

The research evidence includes data on specific patient subgroups, as Loproc was evaluated in pediatric populations (infants and children up to 16 years) and older adults. However, data for certain groups remain insufficient. Long-term effects are not fully established based on the most rigorous study designs, as controlled follow-up durations were often limited to one year. Data for those with multiple comorbidities remain insufficient, and research is ongoing to further clarify these areas.

Key Studies & References

  1. Omeprazole and H-2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis
  2. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
  3. Clinical Pharmacology of Omeprazole in Infants and Children

Frequently Asked Questions (FAQ)

Common questions about Loproc (FAQ)


Q: Is Loproc considered a long-term or short-term treatment?

Loproc is indicated for both short-term treatment and long-term use, depending on the specific condition being addressed. Official regulatory documents list regimens for short periods, such as 4 to 8 weeks for certain ulcers, as well as indications for extended, long-term use, such as the maintenance of healing for erosive esophagitis.


Q: Can I take Loproc if I am also taking vitamins or herbal supplements?

Official drug information explicitly documents a risk of interaction with the herbal supplement St. John's Wort. Because of this, and the potential for interactions between acid-reducing medicines and other products, regulatory labels suggest informing a health professional about all supplements being used.


Q: How does Loproc compare to other medications that treat the same condition?

Studies and official information indicate that Loproc's mechanism, which involves irreversibly blocking the Proton Pump (the final step of acid secretion), is distinct from older acid-reducing agents. Regulatory documents describe this sustained effect on acid production as a key differentiating factor in the study of acid-related conditions.


Q: What is the difference between Loproc and its alternatives (high-level comparison)?

Loproc is classified as a Proton Pump Inhibitor (PPI). The fundamental difference is that PPIs, unlike other classes of acid reducers, work by irreversibly blocking the proton pumps in the stomach lining. This unique action results in strong and sustained acid control. This action defines its utility as a highly effective inhibitor of gastric acid secretion.


Q: Is it necessary to have routine blood tests while taking Loproc?

Routine testing may be necessary in specific situations. For instance, official labeling notes that monitoring of the International Normalized Ratio (INR) is required when Loproc is taken with certain blood thinners. Additionally, because long-term use is associated with a risk of conditions like Vitamin B12 deficiency or low magnesium, these risks may necessitate monitoring.


Q: Is there a generic version of Loproc available?

The active ingredient in Loproc is Omeprazole. Omeprazole is a well-established medicine that is widely available as a generic drug in many countries. Regulatory databases list numerous products containing Omeprazole in its common delayed-release capsule and tablet forms.


Q: Why might Loproc be prescribed instead of a similar drug?

Official regulatory documentation highlights that Loproc is one of the most thoroughly studied Proton Pump Inhibitors (PPIs). It is noted for its potent, sustained acid suppression achieved by irreversibly blocking the proton pump. This highly reliable mechanism for acid control is a key factor in its selection for various acid-related conditions.


Q: Why do some people experience better results with Loproc than others?

Individual response differences are often tied to how the body processes the medication. Regulatory labels note that Loproc is broken down by specific liver enzymes, primarily CYP2C19. The activity of this enzyme can vary significantly between individuals, which in turn can influence the drug's effectiveness and the results a person experiences.


Q: How quickly does Loproc start working after I begin taking it?

According to official product information, the anti-acid effect begins within one hour of taking an oral dose, with the maximum effect usually reached within two hours. However, for a full therapeutic effect or complete symptom relief to be achieved, continuous dosing over 1 to 4 days may be necessary.


Q: How long does the effect of one dose of Loproc last?

Although Loproc leaves the bloodstream relatively quickly, its inhibitory action on acid secretion is long-lasting. This is because the drug binds tightly to the acid pumps. As a result, the sustained anti-acid effect of a single dose can last for up to 72 hours.


Q: Can Loproc be used for conditions other than what it is officially approved for?

Official documentation defines the specific conditions Loproc is indicated to treat. Regulatory bodies do not provide safety or efficacy information for unapproved uses. Its use is limited to the purposes described in the official prescribing information.


Q: Is there a high chance of becoming dependent on Loproc?

Official patient information mentions that stopping the medicine suddenly, especially after long-term use, may lead to a temporary increase in stomach acid production, which is known as rebound hyperacidity. This rebound effect can cause symptoms to return, but acid activity generally returns to normal levels gradually over three to five days.


Q: Are the side effects of Loproc generally temporary?

Many individuals who experience side effects find them to be mild. In many cases, they are described as temporary and resolve following discontinuation of treatment. However, official safety data also details certain rare and serious effects, as well as risks linked to long-term use.


Q: Does Loproc cause weight gain or weight loss?

Weight changes were not reported as a common or uncommon adverse reaction in clinical trials summarized in official documents. However, some post-marketing reports have noted changes in weight. Official labeling notes that unexplained weight loss is a serious symptom that warrants medical review.


Q: Can Loproc affect my ability to drive or operate machinery?

Regulatory safety information indicates that caution is warranted before driving or operating machinery. This is because some reported side effects that may affect this ability include experiencing dizziness or visual disturbances.


Q: Are there any known interactions between Loproc and alcohol?

Explicit warnings in the official instructions state that taking this medicine with alcohol is to be avoided. Official patient information suggests limiting the intake of alcohol during use, which aligns with general health advice while managing acid-related conditions.


Q: Does Loproc interact with common over-the-counter pain relievers?

Official drug interaction lists focus primarily on prescription medications that affect how the medicine is metabolized. While common non-prescription pain relievers are not typically listed, official labeling recommends informing a health professional about all medicines being used, including non-prescription pain relievers.


Q: What types of food or drinks should be avoided while taking Loproc?

Regulatory labels do not define specific food or drink types that must be strictly avoided with Loproc. Information related to acid reflux often describes avoiding foods that typically cause symptoms, but this is general dietary information, not a specific drug restriction.


Q: What is the success rate or effectiveness range reported in studies for Loproc?

Clinical studies show that effectiveness varies widely depending on the specific condition being treated. For example, in trials examining erosive esophagitis, official documents report that Loproc's rate of healing the esophagus is approximately 80%.


Q: Can Loproc be stopped suddenly, or does it require tapering?

Regulatory information highlights the importance of professional guidance before stopping the medicine, especially after long-term use. This is because stopping suddenly can cause a temporary increase in stomach acid (rebound effect). Professional supervision may be used to gradually reduce the dose to prevent symptoms from returning.


Q: Does Loproc contain lactose or gluten, which might be a concern for allergies?

The inactive ingredients list for some Loproc formulations includes lactose monohydrate. Patients with conditions like lactose intolerance are advised to review the inactive ingredients list for their specific product formulation.


Q: What happens if I accidentally take more Loproc than prescribed?

Regulatory safety information states that if more Loproc is taken than prescribed, medical attention is warranted immediately. Symptoms noted in official documents may include dizziness, excessive sleepiness, double vision, slurring of words, or passing out.


Q: Does Loproc affect fertility or reproductive health?

Studies on fertility do not generally suggest that Loproc affects a person's ability to conceive. However, the use of any medication during preconception should be reviewed with a health professional, as official regulatory documents detail use during pregnancy and lactation.


Q: Is Loproc known to cause or worsen anxiety?

Anxiety was not reported as a common side effect in the main clinical trials summarized in official documents. However, it has been noted in post-marketing reports, although the frequency and direct link to Loproc are not clearly established by regulatory bodies.


Q: How long after stopping Loproc might side effects last?

When the medication is discontinued, the body's natural acid-secreting activity returns gradually. Official information indicates this process usually takes between 3 to 5 days. Any temporary rebound symptoms, such as heartburn, may persist for about 2 weeks while the body readjusts its natural acid production.

How should Loproc be stored and disposed of?

Loproc must be stored in its original container at room temperature, typically between 68 F to 77 F (20 C to 25 C). It is essential to keep the medication away from moisture and excessive heat, which can degrade the product's quality and effectiveness. Do not store the medication in the bathroom or near a sink. When handling, keep the product in the outer carton to protect it from light. The medication must be kept in a secure location, out of the reach and sight of children and pets, to prevent accidental ingestion or misuse. Once the product is no longer needed or has expired, do not flush it down the toilet or pour it into a drain unless specifically instructed by the labeling or a healthcare professional. Unused or expired Loproc should be disposed of safely, preferably by utilizing a local medicine take-back program or following guidelines for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loproc found in:

A-Z Index: